Kate Amato Foundation (KAF) recently received a donation of $50,000 from Experian Health, a segment of Experian, a global data and technology company. This significant contribution will prove instrumental in funding innovative pediatric cancer research at leading facilities across the country.
KAF will use the donation to develop safer, smarter and more-effective treatments for children battling cancer.
Pediatric cancer is the leading cause of death by disease in children. Despite this grim reality, only 4% of total federal research funding is allocated to childhood cancers.
Additionally, the pharmaceutical industry’s reluctance to invest in pediatric cancer research, citing the larger and more profitable adult cancer market, highlights the dire need for initiatives like this. Deeming childhood cancer research “not a good investment” only perpetuates the cycle of underfunding and limited treatment options for young patients.
Donations and partnerships like the one with Experian are not just impactful but essential in advancing progress and ultimately saving young lives.
Experian Health serves more than 60% of U.S. hospitals and more than 7,500 medical practices, labs, pharmacies and other health care providers with data and technology that simplifies health care.
Kate Amato Foundation is optimistic about the relationship with Experian Health, anticipating that their shared vision and collaborative efforts will pave the way for transformative advancements in pediatric cancer research and bring renewed optimism to countless young lives. Their hope is that this is the beginning of a long and fruitful partnership and that other companies, as well as individual donors, will follow the lead of Experian Health and join the battle against childhood cancer.
This funding will provide what is desperately needed to develop more effective treatments for children suffering from this disease.
If you would like to donate to the foundation or learn more about their work, go to kateamatofoundation.org.
